AVANT

April 14, 2026

Condensed Interim Consolidated Financial Statements

Three Months Ended
February 28, 2026

(Unaudited - Expressed in Canadian Dollars)

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORTING

The accompanying condensed consolidated interim financial statements of Avant Brands Inc. (the "Company") have been prepared by management in accordance with IAS 34 *Interim Financial Reporting* as issued by the International Accounting Standards Board ("IASB"). Management acknowledges responsibility for the preparation and presentation of the condensed consolidated interim financial statements, including responsibility for significant accounting estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances.

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Canadian Institute of Chartered Professional Accountants for a review of interim financial statements by a company's auditor.

AVANT BRANDS INC.

Condensed Interim Consolidated Statements of Financial Position

As at February 28, 2026 and November 30, 2025

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	Note	February 28, 2026	November 30, 2025
Assets			
Current assets			
Cash		**$763**	$1,485
Trade and other receivables	4	**5,185**	6,579
Due from related party	16	**162**	139
Prepaid expenses and deposits	5	**342**	412
Biological assets	6	**4,756**	5,635
Inventory	7	**6,001**	6,590
		17,209	20,840
Property, plant and equipment	8	**28,129**	27,363
Intangible assets	9	**940**	1,037
Total assets		**$46,278**	$49,240
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities		**$8,548**	$8,002
Legal provision	18	**100**	100
Lease liabilities	10	**1,308**	1,299
Secured credit facility	11	**861**	1,182
Convertible debenture B	12	**637**	1,231
Due to related party	16	**1,521**	1,032
		$12,975	$12,846
Lease liabilities	10	**10,032**	10,106
Secured credit facility	11	**-**	-
Convertible debenture B	12	**1,872**	1,489
Total liabilities		**$24,879**	$24,441
Shareholders' equity			
Share capital	13	**110,910**	110,910
Contributed surplus	13	**11,813**	11,779
Accumulated deficit		**(101,324)**	(97,890)
Total shareholders' equity		**21,399**	24,799
Total liabilities and shareholders' equity		**$46,278**	$49,240

Nature and continuance of operations (Note 1)

Commitments and contingencies (Note 18)

Approved on behalf of the Board on April 13, 2026.

/s/ Derek Sanders, Director

/s/ Tyson Macdonald, Director

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements

AVANT BRANDS INC.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
For the three-month periods ended February 28, 2026 and 2025
(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	Note	February 28, 2026	February 28, 2025
Revenue		**$8,361**	$9,680
Excise taxes		**(1,298)**	(1,077)
Net revenue	15	**7,063**	8,603
Cost of sales		**(5,724)**	(5,680)
Gross profit before fair value changes		**1,339**	2,923
Unrealized gain on changes in fair value of biological assets		**821**	2,873
Change in fair value of biological assets realized through inventory sold		**(2,058)**	(4,212)
Gross profit		**102**	1,584
Operating expenses			
Administration and general		**257**	253
Business fees and licenses		**221**	215
Consulting fees		**179**	219
Brokerage and commission fees		**558**	168
Depreciation and amortization	8,9	**130**	154
Marketing and advertising		**19**	82
Professional fees		**228**	409
Salaries and wages		**1,334**	726
Share based payments	14	**34**	36
Travel		**79**	91
		3,039	2,353
Net loss from operations		**(2,937)**	(769)
Other income (expense)			
Financing costs	10	**(273)**	(2)
Interest and accretion	10,11,12	**(151)**	(149)
Foreign exchange loss		**(2)**	(1)
Provision for legal expenses		**(74)**	-
Interest on related party loan		**3**	-
Net loss before income tax		**$(3,434)**	$(921)
Net loss and comprehensive loss		**$(3,434)**	$(921)
Loss per common share			
Basic and diluted		**$(0.30)**	$(0.09)
Weighted average shares outstanding			
Basic and diluted		**11,407,934**	10,684,446

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements

AVANT BRANDS INC.

Condensed Interim Consolidated Statements of Changes in Equity

For the three-month periods ended February 28, 2026 and 2025

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	Shares	Share capital	Contributed Surplus	Deficit	Total
Balance at November 30, 2024	**10,630,698**	**$109,804**	**$11,061**	**$(88,010)**	**$32,855**
Net loss for the period	-	-	-	(921)	(921)
Share units released	8,333	18	(18)	-	-
Shares issued for services	106,842	405	(405)	-	-
Share based compensation	-	-	38	-	38
Balance at February 28, 2025	**10,745,873**	**$110,227**	**$10,676**	**$(88,931)**	**$31,972**
Balance at November 30, 2025	**11,407,934**	**$110,910**	**$11,779**	**$(97,890)**	**$24,799**
Net loss for the period	-	-	-	(3,434)	(3,434)
Share based compensation	-	-	34	-	34
Balance at February 28, 2026	**11,407,934**	**$110,910**	**$11,813**	**$(101,324)**	**$21,399**

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements

AVANT BRANDS INC.

Condensed Interim Consolidated Statements of Cash Flows

For the three-month periods ended February 28, 2026 and 2025

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	February 28, 2026	February 28, 2025
Net loss	**$(3,434)**	$(921)
Adjustments for non-cash items:		
Unrealized gain on changes in fair value of biological assets	**(821)**	(2,873)
Change in fair value of biological assets realized through inventory sold	**2,058**	4,212
Depreciation and amortization	**130**	1122
Interest and accretion	**151**	297
Interest on related party loan	**(3)**	-
Financing costs	**273**	2
Share-based payments	**34**	38
Provision for legal expenses	**74**	-
	(1,538)	1,877
Changes in working capital		
Trade and other receivables	**1,394**	1,495
Prepaid expenses and deposits	**70**	(449)
Biological assets	**(358)**	(715)
Inventory	**1,511**	(116)
Accounts payable and accrued liabilities	**(1,250)**	(1,002)
Due to related party	**489**	-
Net cash flows generated from operating activities	**$318**	$1,090
Cash flows from investing activities		
Purchase of property, plant and equipment	**(16)**	(2)
Proceeds from legal settlement	**-**	-
Disposal of property and equipment	**-**	-
Proceeds from sale of marketable securities	**-**	-
Net cash flows used in investing activities	**$(16)**	$(2)
Cash flows from financing activities		
Lease liability payments	**(322)**	(354)
Repayment of secured credit facility	**(365)**	(365)
Repayment of convertible debenture A	**-**	(599)
Repayment of convertible debenture B	**(317)**	(413)
Loan issued to related party	**(20)**	(100)
Net cash flows used in financing activities	**$(1,024)**	$(1,831)
Decrease in cash	**(722)**	(743)
Cash – beginning of period	**1,485**	1,740
Cash – end of period	**$763**	$997

The accompanying notes are an integral part of these Condensed Interim Consolidated Financial Statements

1 Nature and continuance of operations

Avant Brands Inc. (the "**Company**") is a corporation where the Company's principal business activity is cultivation, production, marketing and sales of cannabis products and pursuing opportunities in the cannabis industry. The Company was incorporated on September 24, 2012, under the Canada Business Corporations Act and continued under the Business Corporations British Columbia Act effective on July 28, 2017. The Company is a publicly traded company listed on the Toronto Stock Exchange ("**TSX**") (TSX: AVNT), and trades on the OTCQX Best Markets (OTCQX: AVTBF) and Frankfurt Stock Exchange (FRA: 1BU0). The Company's head office is located at Suite 910 – 1700 Dickson Avenue, Kelowna, British Columbia, V1Y 0L5.

These condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes that the Company will be able to continue for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

The Company has incurred losses since inception and has an accumulated deficit of $101,324 as at February 28, 2026, and continues to be funded primarily by the issuance of equity, convertible debentures, and a secured credit facility. The Company's ability to continue as a going concern depends upon its ability to generate profitable operations or continue to raise adequate financing in the future. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be obtained on terms acceptable to the Company. With no assurance that additional financing will be obtained there is a material uncertainty related to the financial conditions that may cast significant doubt on the Company's ability to continue as a going concern and therefore, it may be unable to realize its assets and discharge its liabilities in the normal course of business. The condensed interim consolidated financial statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern.

2 Basis of presentation

Statement of compliance and basis of measurement

The condensed interim consolidated financial statements of the Company have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board ("**IASB**").

The condensed interim consolidated financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended November 30, 2025, and any public announcements made by the Company during the interim reporting period. Selected explanatory notes are included to explain events and transaction that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements.

The accounting policies adopted are consistent with those of the previous financial year, except for the adoption of new and amended standards as set out in Note 3.

These condensed interim consolidated financial statements of the Company were approved and authorized for issue by the Board of Directors of the Company (the "**Board**") on April 13, 2026.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Basis of consolidation

These condensed interim consolidated financial statements include the accounts of the Company and the following Canadian subsidiaries:

Subsidiaries	Geographical Region	Ownership percentage
3PL Ventures Inc. (“**3PL**”)	Vernon, British Columbia	100%
Avant Craft Cannabis Inc. (“**ACC**”)	Edmonton, Alberta	100%
Avant K1 Brands Inc. (“**Avant K1**”)	Kelowna, British Columbia	100%
GreenTec Bio-Pharmaceuticals Corp. (“**GBP**”)	Kelowna, British Columbia	100%
GreenTec Holdings Ltd. (“**GreenTec**”)	Kelowna, British Columbia	100%
Grey Bruce Farms Incorporated (“**Grey Bruce**”)	Tiverton, Ontario	100%
The Flowr Group (Okanagan) Inc. (“**Flowr Okanagan**”)	Kelowna, British Columbia	100%
Tumbleweed Farms Corp. (“**Tumbleweed**”)	Chase, British Columbia	100%

Subsidiaries are entities that the Company controls. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when the Company has existing rights and the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company’s share capital. All inter-company balances and transactions, including unrealized profits and losses arising from intra-group transactions, have been eliminated upon consolidation. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The Company operates as a single reportable segment as the chief operating decision maker monitors the business as a whole and makes decisions based on consolidated financial information. Accordingly, no separate segment information is presented in these financial statements.

3 Adoption of new accounting pronouncements

a) New standards and interpretations not yet adopted:

Certain amendments to accounting standards have been published that are not mandatory for the current reporting period and have not been early adopted by the group. These amendments are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

- Presentation and Disclosure in Financial Statements – IFRS 18
- Classification and Measurement of Financial Instruments – IFRS 9 and IFRS 7

b) New and amended standards adopted by the Company:

The Company has applied the following standards and amendments for the first time for its annual reporting period commencing December 1, 2025. The amendments listed below did not have any impact on the amounts, presentation, classification or disclosure of amounts recognized in prior periods and are not expected to significantly affect the current or future periods.

Amendments to Lack of Exchangeability – Amendments to IAS 21

The Company doesn’t collect foreign currency and has no foreign vendors with a lack of exchangeable currencies.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

4 Trade and other receivables

As of February 28, 2026, and November 30, 2025, trade receivables consisted of:

	February 28, 2026	November 30, 2025
Trade accounts receivable	**$5,185**	$6,155
Other receivables	**-**	424
Total	**$5,185**	$6,579

As of February 28, 2026, and November 30, 2025 the Company performed an analysis over its aged receivables balance by customer. The balance by customer review showed a history of collections from trade and other receivables being reasonably assured. From the review, the Company noted that no further allowance is required, and the Company recognized a $nil provision for AFDA as at February 28, 2026 (November 30, 2025: $nil).

5 Prepaid expenses and deposits

As of February 28, 2026, and November 30, 2025, prepaid expenses and deposits consisted of:

	February 28, 2026	November 30, 2025
Packaging material prepayments	**$-**	$-
Deposits and other	**342**	412
Total	**$342**	$412

6 Biological assets

The changes in the carrying value of biological assets for the three-month period ended February 28, 2026, and twelve-month period ended November 30, 2025 are as follows:

	February 28, 2026	November 30, 2025
Carrying amount, opening	**$5,635**	$6,655
Production costs	**4,666**	19,801
Changes in fair value less costs to sell due to biological transformation	**821**	8,116
Transferred to inventory upon harvest	**(6,366)**	(28,937)
Total	**$4,756**	$5,635

As at February 28, 2026, it is estimated that the Company's biological assets will yield approximately 1,814 kilograms of flower (November 30, 2025: 2,047 kilograms) and 507 kilograms of trim when harvested (November 30, 2025: 421 kilograms). The Company's biological assets yielded 3,006 kilograms of cannabis for the three-month period ended February 28, 2026 (February 28, 2025: 3,326 kilograms).

As at February 28, 2026, the Company has determined the average fair value less cost to sell to be $2.62 per gram of flower (November 30, 2025: $2.75) and $nil per gram of trim (November 30, 2025: $nil).

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

As of February 28, 2026, a change of 10% in the estimated yield per plant, growth cycle, and fair value less cost to sell of dry cannabis would result in the variances noted below to the fair value of biological assets:

Assumption	**February 28, 2026**	**+/- 10%**
Yield per plant	58 - 96 grams of flower and 19 - 22 grams of trim per plant	$476
FV less cost to sell	$2.62 per gram of flower and $nil per gram of trim	485
Estimated stage of growth	0% - 100% of life cycle per stage	476

7 Inventory

The Company's inventories are comprised of the following balances as at February 28, 2026 and November 30, 2025:

	February 28, 2026	November 30, 2025
Dry cannabis		
Available for packaging	**$5,308**	$5,990
Packaged inventory	**693**	600
Packaging materials	**-**	-
Total	**$6,001**	$6,590

As at February 28, 2026, the Company holds 3,659,575 grams of harvested cannabis (November 30, 2025: 3,066,854 grams), which is comprised of 2,283,281 grams of harvested flower and 1,376,294 grams of harvested trim (November 30, 2025: 2,494,656 grams of harvested flower and 572,198 grams of harvested trim). The Company recognized $5,724 as inventory expense relating to cannabis sold during the three-month period ended February 28, 2026 (February 28, 2025: $5,680).

During the three-month period ended February 28, 2026, the Company capitalized $5,418 of costs (February 28, 2025: $10,296) to inventory.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

8 Property, plant and equipment

	Land	Buildings	Construction in process	Growing and processing equipment	Right-of-use assets	Leasehold improvements	Other	Total
Cost								
Balance – November 30, 2024	$1,348	$9,300	$3,212	$13,342	$11,952	$7,962	$377	$47,493
Additions	-	-	-	14	616	-	19	649
Disposals	-	-	(4)	(1,651)	(18)	(1,141)	-	(2,814)
Impairment	-	-	(1,700)	27	-	-	(27)	(1,700)
Lease modification	-	-	-	-	986	-	-	986
Balance – November 30, 2025	$1,348	$9,300	$1,508	$11,732	$13,536	$6,821	$369	$44,614
Additions	-	-	1,722	16	-	-	-	1,738
Disposals	-	-	-	-	-	-	-	-
Transfer	-	-	-	-	-	-	-	-
Lease modification	-	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-	-
Balance – February 28, 2026	**$1,348**	**$9,300**	**$3,230**	**$11,748**	**$13,536**	**$6,821**	**$369**	**$46,352**
Accumulated depreciation								
Balance – November 30, 2024	$-	$(2,909)	$-	$(5,051)	$(2,778)	$(4,591)	$(342)	$(15,671)
Additions	-	(462)	-	(1,472)	(866)	(1,347)	(10)	(4,157)
Disposals	-	-	-	1,436	-	1,141	-	2,577
Balance – November 30, 2025	$-	$(3,371)	$-	$(5,087)	$(3,644)	$(4,797)	$(352)	$(17,251)
Additions	-	(115)	-	(332)	(184)	(337)	(4)	(972)
Disposals	-	-	-	-	-	-	-	-
Balance – February 28, 2026	**$-**	**$(3,486)**	**$-**	**$(5,419)**	**$(3,828)**	**$(5,134)**	**$(356)**	**$(18,223)**
Net book value								
Balance - November 30, 2025	$1,348	$5,929	$1,508	$6,645	$9,892	$2,024	$17	$27,363
Balance – February 28, 2026	**$1,348**	**$5,814**	**$3,230**	**$6,329**	**$9,708**	**$1,687**	**$13**	**$28,129**

During the three-month period ended February 28, 2026, the Company allocated $785 (February 28, 2025: $971) of depreciation expense to cost of inventory. On December 5, 2025, the Company entered into an agreement with a government agency to receive $2 million to improve lighting efficiency at Flowr Okanagan. Recognition of the government grant is contingent upon completion of the lighting improvement project.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

9 Intangible assets and goodwill

The Company's intangible assets consist of licenses to sell cannabis and have definite lives. The Company completes an annual assessment of the recoverable amount of the goodwill.

	Intangible asset	Goodwill	Total
Cost			
Balance – November 30, 2024	$5,589	$6,024	$11,613
Disposal	(3,202)	-	(3,202)
Balance – November 30, 2025	2,387	6,024	8,411
Disposal	-	-	-
Balance – February 28, 2026	**$2,387**	**$6,024**	**$8,411**
Accumulated amortization and impairment			
Balance – November 30, 2024	$(4,166)	$(6,024)	$(10,190)
Amortization	(386)	-	(386)
Impairment	3,202	-	3,202
Balance – November 30, 2025	(1,350)	(6,024)	(7,374)
Amortization	(97)	-	(97)
Disposal	-	-	-
Balance – February 28, 2026	**$(1,447)**	**$(6,024)**	**$(7,471)**
Net book value			
Balance – November 30, 2025	$1,037	-	$1,037
Balance – February 28, 2026	**$940**	-	**$940**

10 Lease liabilities

The following is a continuity schedule for lease liabilities:

Balance – November 30, 2024	$10,196
Lease modification	937
Lease additions	616
Lease termination	(21)
Lease payments	(1,386)
Interest expense on lease liability	1,063
Balance – November 30, 2025	$11,405
Lease payments	(322)
Interest expense on lease liability	257
Balance – February 28, 2026	**$11,340**
Current portion	**$1,308**
Long-term portion	**$10,032**

For a breakdown of future lease payments, refer to Note 17.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

11 Secured credit facility

The following is a continuity schedule for the secured credit facility:

Secured facility financial liability, November 30, 2024	$2,325
Principal and interest payments	(1,461)
Interest and accretion	318
Secured facility financial liability, November 30, 2025	$1,182
Principal and interest payments	(365)
Interest and accretion	44
Secured facility financial liability, February 28, 2026	**$861**
Warrants - equity instrument, November 30, 2024	$84
Warrants - equity instrument, November 30, 2025	$84
Warrants - equity instrument, February 28, 2026	**$84**
Secured facility current portion	**$861**
Secured facility long-term portion	**$-**

12 Convertible debenture B

The following is a continuity schedule for convertible debenture B:

Liability component carrying value, November 30, 2024	$3,602
Principal and interest payments	(1,399)
Interest and accretion	517
Liability component carrying value, November 30, 2025	$2,720
Principal and interest payments	(317)
Interest and accretion	106
Liability component carrying value, February 28, 2026	**$2,509**
Equity conversion option, November 30, 2024	$226
Debt modification – Derecognition of equity conversion option	(226)
Reclassification to equity conversion option	472
Equity conversion option, November 30, 2025	$472
Debt modification – Derecognition of equity conversion option	-
Reclassification to equity conversion option	-
Equity conversion option, February 28, 2026	**$472**
Liability component current portion	**$637**
Liability component long-term portion	**$1,872**

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

13 Share capital

The Company has an unlimited number of common shares without par value authorized for issuance. The Company also has an unlimited number of preference shares without par value authorized for issuance.

(a) Issued shares

During the three months ended February 28, 2026:

(i) No movement.

During the three-month period ended February 28, 2025:

(ii) The Company issued 8,333 common shares in connection with employment compensation agreements and share units released, resulting in a decrease to contributed surplus of $18 and an increase in share capital of $18.

(iii) The Company issued 106,842 common shares to service providers in connection with services received, resulting in a decrease to contributed surplus of $405 and an increase in share capital of $405.

(b) Share purchase warrants

Share purchase warrants ("**warrants**") transactions are summarized as follows:

	Number of warrants	Weighted average exercise price
Balance – November 30, 2024	2,045,446	$4.47
Granted	1,425,000	1.60
Expired	(166,667)	15.00
Cancelled	(1,300,000)	3.00
Balance – November 30, 2025	2,003,779	$2.51
Granted	-	-
Expired	(45,833)	7.50
Cancelled	-	-
Balance – February 28, 2026	**1,957,946**	**$2.39**

The weighted average outstanding life of warrants outstanding as at February 28, 2026, is 2.08 years (November 30, 2025: 2.28 years).

As at February 28, 2026 the following warrants were outstanding:

Number of warrants	Exercise price per share	Expiry date
58,333	$9.00	July 14, 2026
474,613	$3.60	June 3, 2027
1,300,000	$1.75	July 26, 2028
125,000	$1.00	September 28, 2028
1,957,946		

14 Stock-based compensation

(a) Share-based payments

During the three-month period ended February 28, 2026, the Company recorded share-based payment expense of $34 (February 28, 2025: $36).

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

The share-based payments represent the fair value of restricted and deferred stock units vested during three-month period ended February 28, 2026, and are estimated on the grant date using the Black-Scholes option pricing model. The share-based payments also consist of common shares issued for services during the year.

(b) Restricted Stock Unit ("RSU") and Deferred Stock Unit ("DSU")

RSU and DSU transactions are summarized as follows:

	Number of RSUs and DSUs	Weighted average issue price
Balance – November 30, 2024	222,853	$5.31
Granted	875,644	1.12
Vested and released	(168,642)	0.80
Forfeited	(24,167)	3.00
Balance – November 30, 2025	905,688	$2.16
Granted	-	-
Vested and released	-	-
Forfeited	-	-
Balance – February 28, 2026	**905,688**	**$2.16**

The weighted average outstanding life of RSUs outstanding as at February 28, 2026, is 0.98 years. Share-based payments included $34 of RSU and DSU expense.

As at February 28, 2026, the following RSUs and DSUs were outstanding:

Number of RSUs and DSUs	Grant date	Vesting Date
10,606	February 23, 2024	Mar. 1, 2026, Mar. 1, 2027
4,762	July 5, 2024	Jun. 22, 2026
13,333	August 6, 2024	Aug. 6, 2026, Aug. 6, 2027
193,750	March 10, 2025	Mar. 3, 2027
53,123	March 1, 2022	Mar. 1, 2022, Jun. 1, 2022, Sep. 1, 2022, Dec. 1, 2022, Mar. 1, 2023
19,444	January 9, 2023	Apr. 14, 2023, Jul. 15, 2023, Oct. 15, 2023, Feb. 28, 2024
24,242	July 29, 2024	Feb. 23, 2024, Apr. 23, 2024, Aug. 23, 2024, Sep. 23, 2024
571,428	March 3, 2025	Mar. 3, 2025
15,000	June 2, 2025	Jun. 2, 2026, Jun. 2, 2027, Jun. 2, 2028
905,688		

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

15 Net revenue

The Company's total net revenues can be found below.

	February 28, 2026	February 28, 2025
Recreational revenue	**$4,056**	$3,018
Provision for sales returns and allowances	**(200)**	(200)
Net recreational revenue	**$3,856**	$2,818
Domestic wholesale revenue	**1,605**	921
Export wholesale revenue	**1,567**	4,690
Medical revenue	**-**	22
Management fees and other revenue	**35**	152
Total	**$7,063**	$8,603

16 Related party transactions

Key management compensation

All transactions with related parties have occurred in the normal course of operations. Key management is comprised of directors and executive officers.

Key management compensation for the three-month periods ended February 28, 2026, and February 28, 2025, consists of the following:

	February 28, 2026	February 28, 2025
Salaries and wages	**$119**	$135
Director fees	**34**	45
Share-based payments	**9**	11
Total	**$162**	$191

Certain key management personnel services are provided by a third party. The Company incurred $45 for the three-month period ended February 28, 2026 (February 28, 2025: $45) for the provision of key management personnel services provided by the third party.

Related party balances

As at February 28, 2026, due to related party payable included $159 (November 30, 2025: $167) due to directors of the Company in connection with accrued directors' fees and $1,362 (November 30, 2025: $865) due to officers of the company in connection with accrued compensation. Both of these balances are unsecured with no associated guarantees and no fixed repayment date.

Related party transactions

Due from related party receivable included a loan made to a related party where the Company issued $150 through various tranches as part of a short-term loan agreement to a related party. The balance includes a tranche extended on December 22, 2025 of $20. The loan bears interest at 8.5%. The loan has no associated guarantee nor fixed repayment date. The loan has incurred interest income of $3 for the three-month period ended February 28, 2026.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

17 Financial instruments

(a) Maturity risk

Typically, the Company targets that it has sufficient cash on hand to meet expected operational expenses and commitments for a period of 90 days. To achieve this objective, the Company prepares annual operating and capital expenditure budgets, which are regularly monitored and updated as considered necessary.

The following table summarizes the maturities of the Company's financial liabilities as at February 28, 2026, based on the undiscounted contractual cash flows:

	Carrying value	Contractual cash flows	< 1 year	1 - 5 years	>5 years
Accounts payable and accrued liabilities	$8,548	$8,548	$8,548	$-	$-
Lease liabilities	11,340	21,539	1,299	5,459	14,781
Secured credit facility	861	904	904	-	-
Convertible debenture B	2,509	3,078	1,206	1,872	-
Total	**$23,258**	**$34,069**	**$11,957**	**$7,331**	**$14,781**

(b) Fair value classification of financial instruments

Below is a comparison, by class, of the carrying amounts and fair values of the Company's financial instruments, other than those with carrying amounts that are reasonable approximations of fair values.

	Amortized cost	Fair Value
Liabilities		
Convertible debenture B	$2,509	$-
Secured credit facility	861	-

18 Commitments and contingencies

From time to time, the Company is engaged in various legal proceedings and claims that have arisen in the normal course of business. The following table summarizes the legal provision outstanding as at February 28, 2026:

Legal provision balance, November 30, 2024	$1,000
Legal provision accrued	212
Legal settlement	(1,112)
Legal provision balance, November 30, 2025	$100
Legal provision accrued	74
Legal settlement	(74)
Legal provision balance, February 28, 2026	**$100**

During the three-month period ended February 28, 2026, the Company accrued $74 for legal provision. The Company recognized legal provisions of $74 in relation to lawsuits resolved.

Additionally, the Company may enter into contracts for services in the normal course of operations. The Company's current contractual commitments vary in terms and can be terminated upon sufficient notice. The Company has the following outstanding commitments based on achieving certain milestones.

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

GBP commitment

As at February 28, 2026, in connection with a previously completed asset acquisition, the Company has committed to issue common shares at a deemed subscription price equal to the greater of the ten day volume weighted average trading price or $30 per common share. The total contingency is valued at $2,500 based on the following events:

Trigger event	
Completion of GBP construction of a Health Canada approved cannabis production facility in compliance with the CA&R	$500
GBP obtaining a license to sell cannabis under the CA&R	500
GBP having sold an aggregate of 3,000 kg of dried cannabis	750
GBP completing construction of an expansion to its production facility to increase production by at least 8,500 kg per annum and receiving an amendment to its production and sales licences	750
	$2,500

19 Comparative figures

Change in presentation of expenses

The Company reclassified a portion of expenses previously presented as Consulting fees into Brokerage and commission fees to more accurately reflect the nature of the expenses incurred.

For the three-month period ended February 28, 2025, $168 was reclassified from Consulting fees to Brokerage and commission fees.

This reclassification reflects changes in the Company's business activities and cost structure, thereby improving comparability between periods. The reclassification has no impact on total operating expenses, profit or loss, cash flows, assets, or liabilities.

20 Subsequent events

On March 4, 2026, the Company entered into an agreement to settle $495 due to related party balance in exchange for 605,493 shares at a deemed price of $0.817. The Company also settled $200 of additional due to related party balance in exchange for 287,998 shares at a deemed price of $0.694.

On March 5, 2026, the Company entered into an agreement to settle $359 due to a vendor in exchange for 535,496 shares at a deemed price of $0.67.

On March 9, 2026, the Company entered into an agreement to extinguish $1,777 of Convertible Debenture B in exchange for 1,900,000 units. Each unit consists of one share and half a share purchase warrant exercisable at $0.935.